Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLAA2-positive patients and pharmaceutical comprising the same

Details for Australian Patent Application No. 2006277295 (hide)

International Classifications

Event Publications

3 April 2008 PCT application entered the National Phase

PCT publication WO2007/018199 Priority application(s): WO2007/018199

23 December 2010 Assignment before Grant

Kumamoto University The application has been assigned to ONCOTHERAPY SCIENCE, INC.

14 July 2011 Amendment Made

The nature of the amendment is: Amend the invention title to read Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLAA2-positive patients and pharmaceutical comprising the same

11 August 2011 Application Accepted

Published as AU-B-2006277295

8 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.